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We describe a ds-oligonucleotide-peptide conjugate that is able to efficiently dismount preformed DNA 
complexes of the bZIP regions of oncoproteins c-Fos and c-Jun (AP-1), and therefore might be useful as 
disrupters of AP-1-mediated gene expression pathways. 
Introduction 
Gene expression is a highly regulated process that involves the 10 
interaction of proteins called transcription factors (TFs) with 
specific regulatory sites of the genome.1 The dysfunctional 
activity of TFs can lead to errors in the expression of specific 
gene products, and eventually to anomalous behaviour of the 
cells.2 When TFs are involved in the regulation of cell 15 
proliferation events, such as in the case the oncoprotein c-Jun, 
this irregular behaviour might result in uncontrolled cell 
proliferation and cancer.3 In fact, there is a large number of 
evidences on the presence of unusual levels of c-Jun in different 
types of human cancers, which suggest that this protein plays a 20 
role in the malignant transformation of cells.4 Therefore, there is 
a high interest on the development of strategies that enable to 
control the activity of this transcription factor.5  
 The mechanism of action of c-Jun involves the formation of a 
coiled-coil heterodimer with other bZip protein components, 25 
prominently with c-Fos, to form the so-called AP-1 complex with 
specific DNA sites (5'–ATGACTCAT–3').6 Earlier reports using 
this heterodimerization complex as reference, have shown that it 
is possible to trap c-Jun into an inactive complex by using 
recombinant proteins featuring the leucine zipper region of  30 
c-Fos.7  This strategy was more effective when the leucine zipper 
region of c-Fos is modified with an acidic tail designed to 
increase the affinity by introducing stabilizing electrostatic 
interactions with the (positively charged) basic region of c-Jun.8 
Therefore, the specificity of these systems relies exclusively on 35 
the leucine zipper component of the sequestering agent, which is 
complementary to that of c-Jun.  
We have previously reported oligonucleotide-peptide conjugates 
that are also capable of interacting with the oncoprotein c-Jun.9 
These systems presented a bivalent surface for the specific 40 
simultaneous recognition of both the leucine rich, and the basic 
region of c-Jun. Unfortunately, although these designs were able 
to trap the bZIP region of Jun with good affinity at 4 ºC, the 
interaction was relatively weak and independent of the 
oligonucleotide sequence. Therefore, the conjugates worked as 45 
the previously described dominant negative peptides, in which 
the oligonucleotide unit is just providing a negatively charged 
surface to favour contacts with the basic region of c-Jun. 
Moreover, these oligonucleotide-peptide conjugates were not able 
to disrupt preformed AP-1/DNA complexes.  50 
 We have now redesigned the system, and are pleased to report 
the discovery of a hybrid that binds the bZIP domain of c-Jun at 
room temperature with high affinity. The interaction of c-Jun 
with the designed conjugate involves specific contacts of both the 
leucine zipper region and the oligonucleotidic unit. Importantly, 55 
the optimized system allows disassembling of a preformed AP-1 
complex. 
Results and Discussion 
Design an optimization of the dsDNA-peptide conjugates 
Our previous constructs consisted of a 35 amino acid sequence of 60 
c-Fos (residues 158-192) connected through the N terminus to a 
5’-thiol terminated oligonucleotide fragment, and featuring a 
four-base separation between the 5’ end and the consensus 
binding sequence of c-Jun (TCAT). As commented before, gel 
shift experiments demonstrated that the interaction of the 65 
conjugates with c-Jun at 4 ºC was independent of the dsDNA 
sequence,9 suggesting that the basic region of c-Jun interacts with 
the polyphosphate surface in a nonspecific manner, instead of 
being inserted in the DNA groove forming specific contacts with 
the edges of the bases, as happens in the natural AP-1 complex. A 70 
qualitative model based on the X-ray structure of the DNA/AP-1 
complex suggested that the inability to form specific contacts 
could arise from an inappropriate arrangement of the c-Jun DNA 
binding site, which would not allow a strain-less insertion of the 
c-Jun basic region into the DNA major groove. We envisioned 75 
that having a five or even six-base pair spacer between the 
consensus binding sequence of c-Jun and the 5’ end of the DNA 
might increase the flexibility of the system, thereby allowing the 
insertion of the basic region into the groove (Fig. 1). On the other 
hand, since our previous double stranded oligonucleotide-peptide 80 
conjugates also underwent partial dehybridization in the binding 
assays, we decided to use slightly longer oligonucleotide chains 
to increase the thermal stability. 
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Fig. 1 Strategy for the specific recognition of the bZIP domain of the 
oncoprotein c-Jun using ds-oligonucleotide-peptide conjugates. The 
question mark indicates the (initially unknown) number of base pairs 
separating the cognate binding site and the 5’-end of the conjugate. 5 
 Peptide 1 that contains the leucine-rich region of c-Fos and 
incorporates a maleimide moiety at the N-terminus, was 
synthesized on a Rink–4-methyl-benzhydrylamine resin 
following standard Fmoc/t-Bu protocols.10 The N-terminal  
maleimide unit was introduced in a final coupling step by using 10 
N-maleoyl-β-alanine. Side-chain deprotection and cleavage from 
the resin (TFA/Et3SiH/H2O, 95 : 3 : 2) afforded the desired 
peptide in a reasonable yield (approximately 12%) and with high 
purity, as deduced from RP-HPLC analysis. Miniproteins Fos and 
Jun, which feature the b-ZIP (basic and leucine rich) regions of 15 
the natural proteins c-Fos and c-Jun,11 were obtained by solid 
phase synthesis, using a PAL-PEG-PS resin following standard 
procedures. Side-chain deprotection and cleavage from the resin 
(TFA/EDT/H2O/TIS, 94 : 2.5 : 2.5 : 1) afforded the required 
peptides. 20 
 The coupling reactions between 5’-thiol-terminated 
oligonucleotides and the maleimide-equipped peptide were 
carried out by stirring the oligonucleotides (50 µM) with a three-
fold excess of the peptide at room temperature (rt), in an aqueous 
buffer containing 10 mM Tris·HCl and 100 mM NaCl at pH 7.5 25 
(Scheme 1). RP-HPLC monitoring of the reaction revealed the 
relatively rapid formation of new products that had the 
chromatographic and spectroscopic characteristics expected for 
the oligonucleotide–peptide conjugates (λmax: 220 and 260 nm, 
full conversion after 30 min). After HPLC purification, the 30 
identity of the products was confirmed by MALDI-MS (see the 
ESI). The annealing of all conjugates with their corresponding 
complementary DNA strands was achieved by mixing 
equimolecular amounts of the conjugates with their 
complementary oligonucleotides in phosphate buffer 10 mM, 35 
NaCl 100 mM, pH 7.5. The double stranded derivatives will be 
named with the suffix ds. 
 
Scheme 1 Reaction sequence for the synthesis of oligonucleotide-peptide 
conjugates, exemplified for the case of conjugate C1. The consensus 40 
binding site for c-Jun is shown in bold. 
 In addition to C1, which includes a four-base pair distance 
between the consensus binding sequence of c-Jun and the 5’ end 
of the DNA, we also prepared C2 and C3, which have 
respectively one and two more spacing bases. We also 45 
synthesized C4, which lacks the c-Jun binding sequence, and 
conjugates with single mutations in the recognition sequence 
(C2G5T and C2C7T) as controls for specificity.  
 
Scheme 2. Sequences of the synthesized ss-oligonucleotide-peptide 50 
conjugates.  
Interaction assays of Jun with the oligonucleotide-peptide 
conjugates 
With the ds-oligonucleotide–peptide conjugates at hand, we were 
in position to run preliminary binding assays with Jun, which 55 
contains the bZIP functional region of the natural protein c-Jun. 
The interaction was studied by electrophoretic mobility shift 
assays (EMSA) under non-denaturing conditions.12 As shown in 
the gel-shift results (Fig 2a), we observed the formation of 
retarded bands when Jun was added to the double-stranded 60 
conjugates C1ds, C2ds, C3ds. Interestingly, we observed 
qualitative differences in the binding properties of the three 
conjugates, with the ones featuring a five or a six base pair spacer 
between the edge of the DNA and the target sequence showing a 
better affinity. In particular, C2ds, which contains a 5-base pair 65 
spacing, is the one presenting the best properties in terms of 
affinity. This result confirmed our initial hypothesis that the 
spacer between the 5' end of the DNA and the consensus-binding 
site of c-Jun has an important influence in the formation of the 
complex. 70 
 We next ran several control binding assays in order to study 
the specificity of the interaction. Importantly, a conjugate that 
features a dsDNA in which the consensus c-Jun binding sequence 
has been fully mutated (C4ds) failed to elicit retarded bands 
when treated with the same concentrations of Jun than in the 75 
experiments above (Fig 2b, lanes 2-4). Moreover, even the 
conjugates in which the oligonucleotide sequence exhibits a 
single mutation in the consensus recognition site (C2G5Tds and 
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ability (Fig 2b, lanes 5-10). 
 
Fig. 2 EMSA analysis of Jun binding to ds-oligonucleotide-peptide 
conjugates at 22 ºC (SyBR gold staining). a) Lane 1: C1ds 50 nM; Lanes 
2-4: C1ds 50 nM with Jun 250, 500 and 1000 nM; Lanes 5-7: C2ds 50 5 
nM with Jun 250, 500 and 1000 nM; Lanes 8-10: C3ds 50 nM with Jun 
250, 500 and 1000 nM. b) Lane 1: C4ds 50 nM; Lanes 2-4: C4ds 50 nM 
with Jun 250, 500 and 1000 nM; Lanes 5-7: C2G5Tds 50 nM with Jun 
250, 500 and 1000 nM; Lanes 8-10: C2C7Tds 50 nM with Jun 250, 500 
and 1000 nM. For details in the conditions of the assays, see 10 
Experimental Section.  
 A titration with Jun using C2ds containing a 32P radioactively 
labelled strand, revealed a dissociation constant of ≈ 201 nM at 
room temperature (see Fig. S1 and S2 in the ESI). To obtain a 
more quantitative characterization of the recognition process, we 15 
also performed fluorescence anisotropy titrations. Thus, 
incubation of a fluorescein-labelled C2ds with increasing 
amounts of Jun resulted in a progressive increase of the 
anisotropy, which was consistent with the formation of a complex 
with higher molecular weight and reduced mobility.13 Fitting the 20 
resulting data to a 1:1 binding model allowed to calculate its 
dissociation constant (Kd ≈ 362 nM) at 22ºC.  
 A qualitative assessment of structural changes associated to the 
formation of the complex between the conjugate C2ds and Jun 
was obtained by circular dichroism. Therefore, while C2ds and 25 
the protein Jun are poorly structured as isolated entities (Fig. 3 
right, dashed lines), mixing them in equimolar amounts produces 
an increase in the negative ellipticity of the bands at 208 and 222 
nm that correlates with an increase of α-helical content of these 
species, as expected for the formation of the complex. Moreover, 30 
the CD spectrum also indicates a small increase in the intensity of 
the negative peak at 275 nm upon addition of Jun, which 
suggests that there is some degree of unwinding in the DNA 
structure.14  
 With the conjugate C2ds at hand, we were in position to assess 35 
whether it could interfere with or even destroy the AP-1/DNA 
complex. Toward this end, a 32P-labelled double stranded (ds) 
oligonucleotide containing the AP-1 binding site was incubated 
with equimolecular amounts of Fos and Jun to give the expected 
complex as deduced from the formation of a retarded EMSA 40 
band (Fig 4, lane 2).15 Gratifyingly, incubation of this mixture 
with increasing amounts of the ds conjugate C2ds promoted the 
progressive disappearance of the slower migrating band. A 
titration allowed us to calculate an IC50 of ≈ 491 nM (see Fig. S3 
in the ESI). 45 
 
Fig. 3 Left: Fluorescence anisotropy titration at 518 nm of a fluorescein-
labelled C2ds (50 nM) with increasing amounts of Jun at 22 ºC in 10 mM 
Tris·HCl (pH 7.5), and best fit to a simple 1:1 binding model. Right: 
Circular Dichroism of C2ds in presence of Jun at 22 ºC in 10 mM 50 
Tris·HCl (pH 7.5), 100 mM NaCl. Dashed lines: (◇) Jun (5 µM); (○) 
C2ds (5 µM). Solid line (●) C2ds (5 µM) with Jun (5 µM). 
Therefore, this result demonstrates that our  
ds-oligonucleotide-peptide conjugate C2ds is not only capable of 
binding free Jun, but it can also disrupt preformed AP-1-like 55 
complexes. 
 
Fig. 4 EMSA analysis of the competition assay of DNA/Fos-Jun 
complex with increasing amounts of conjugate C2ds at 22 ºC Lane 1-9: 
32P-radiolabelled dsDNA 90 pM; Lane 2: with Fos and Jun 500 nM; Lane 60 
3-9: same as lane 2 with increasing amounts of conjugate C2ds: 150, 250, 
400, 550, 800, 1000 and 1250 nM. See the Experimental Section for 
details. 
 A control experiment using the conjugate C2, which contains a 
single-stranded oligonucleotide strand, revealed that, as expected, 65 
this compound is not able to disassemble the AP-1/DNA complex 
(Fig. 5., lane 3). However, addition to the previous mixture of a 
DNA strand complementary to that in conjugate C2 promoted the 
disappearance of the band corresponding to the AP-1 complex 
(Fig 5, lane 4). This experiment, in addition to confirmimg the 70 
requirement of the dsDNA to provide a specific interaction site 
for the basic region of Jun, also hints to an interesting strategy 
for the conditional activation of the system by using external 
ssDNAs. 
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Fig. 5 EMSA analysis of the disruption of the AP-1 complex at 22 ºC. a) 
Lane 1-4: 32P-radiolabelled dsDNA 90 pM; Lane 2: with Fos and Jun  
500 nM; Lane 3: same as lane 2 with conjugate C2 1500 nM; Lane 4: 
same as lane 3 with complementary DNA strand to conjugate C2 1500 5 
nM. b) Illustration of the conditional sequestration of Jun and consequent 
AP-1 disruption. 
Conclusions 
In summary, our data demonstrate that an appropriately designed 
peptide-oligonucleotide conjugate that present both a DNA and a 10 
peptidic recognition surface can bind transcription factors 
fragments by means of a specific, bivalent interaction, and even 
disrupt their DNA complexes. This strategy offers unique 
opportunities to exploring relevant biomolecular recognition 
processes, as well as to developing new types of conditional 15 
decoy platforms for specific sequestration of transcription factors 
that, as c-Jun, are involved in the progress of prominent diseases 
like cancers.  
Experimental Section 
Peptide synthesis  20 
All peptide synthesis reagents and amino acid derivatives were 
purchased from GL Biochem (Shanghai) and NovaBiochem; 
standard amino acids were purchased as protected Fmoc amino 
acids with the standard side chain protecting scheme. C-terminal 
amide peptides were synthesized using a 0.66 mmol/g loading 25 
Rink-MBHA amide resin from GL Biochem (Shanghai) or a 0.21 
mmol/g loading Fmoc–PAL–PEG–PS resin from Applied 
Biosystems. All other chemicals were purchased from Sigma-
Aldrich. All solvents were dry and synthesis grade, except DMF 
for peptide synthesis. 30 
 The synthesis of peptide 1 was carried out manually on a Rink-
MBHA amide resin (0.66 mmol/g, 0.3 mmol scale) using the 
following protocol: 1) DMF washings, 5  1 min; 2) 
piperidine/toluene/ DMF (2:1:7, 10 mL), 2  2 min; 3) DMF 
washings, 4  1 min; 4) CH2Cl2 washing, 2  1 min; 5) Fmoc-35 
amino acid (8 eq, 2.4 mmol) and DIC (4 eq, 1.2 mmol) in DMF / 
CH2Cl2 (3 mL/0.6 mL), 1 h. The completion of the coupling 
reaction was monitored using Kaiser and NF-31 tests. If one of 
the tests was positive, the coupling reaction was repeated with 4 
eq of Fmoc-amino acid, HOAt (4 eq, 1.2 mmol) and HBTU (4 eq, 40 
1.2 mmol) and DIEA (8 eq, 2.4 mmol) in DMF (2 mL). After 
coupling of the last arginine, an aliquot of resin-bound peptide 
(50 mg, 0.01 mmol scale) was separated and it was reacted with a 
solution of N-maleoyl-β-alanine (BMPA, 5 eq, 8.5 mg, 0.05 
mmol), HOAt (5 eq, 6.8 mg, 0.05 mmol), HBTU (5 eq, 19.0 mg, 45 
0.05 mmol) and DIEA (10 eq, 17 µL, 0.1 mmol) in DMF (600 
µL). The cleavage/deprotection step was performed by treatment 
of the resin-bound peptide with the following mixture: 950 µL of 
TFA, 30 µL of Et3Si and 20 µL of H2O (300 µL of this mixture 
for 10 mg of resin). After precipitation in Et2O, the peptide was 50 
dissolved in H2O / 0.1% TFA (500 µL). Reversed-phase HPLC 
analysis (performed using an Agilent 1100 series Liquid 
Chromatograph Mass Spectrometer system, Zorbax Eclipse XDB-
C18 (5 µm) 4.6  150 mm analytical column from Agilent, 
gradient of 5 to 95% CH3CN, 0.1% TFA / H2O, 0.1% TFA over 55 
30 min, detection at 220 nm, Electrospray Ionization Mass 
Spectrometry (ESI/MS) (performed with an Agilent 1100 Series 
LC/MSD VL G1956A model in positive scan mode) revealed that 
conjugate 1 elutes with a retention time of 13.5 min. The 
purification of the peptide was performed on a Jupiter Proteo 60 
90A (4 µm) 10  250 mm reverse-phase column from 
Phenomenex and the peptide was identified by ESI/MS ([MH]+ 




5+). Approximate yield for the 
whole process 12%. 65 
 The miniprotein Fos was synthesized using an automatic 
peptide synthesizer from Protein Tecnologies PS3 Peptide 
Synthesizer on a Fmoc–PAL–PEG–PS resin (0.21 mmol/g, 0.05 
mmol scale). The amino acids were coupled in 4-fold excess 
using HBTU as activating agent. Each amino acid was activated 70 
for 30 seconds in DMF before being added onto the resin. Peptide 
bond-forming couplings were conducted for 30 min to 45min. 
The deprotection of the temporal Fmoc protecting group was 
performed by treating the resin with 20% piperidine in DMF 
solution for 10 min. The cleavage/deprotection step was 75 
performed by treatment of the resin-bound peptide (0.02 mmol) 
with 3 mL of the cleavage cocktail (75 µL of 1,2-ethanedithiol 
(EDT), 75 µL of water,  
30 µL of triisopropylsilane (TIS) and TFA to 3 mL) for 3 h. After 
precipitation in Et2O, the peptide was redissolved in 80 
acetonitrile/water 1:1 (1 mL). Reversed-phase HPLC analysis 
(same conditions as peptide 1, gradient of 15 to 95% CH3CN, 
0.1% TFA / H2O, 0.1% TFA over 30 min) revealed that Fos 
elutes with a retention time of 15.5 min. The purification of the 
peptide was performed on a Jupiter Proteo 90A (4 µm) 10  250 85 
mm reverse-phase column from Phenomenex and the peptide was 
identified by ESI/MS ([MH]+ calculated for C290H503N99O90S3 




24% yield for 0.02 mmol scale. 
 Jun was purchased from Eurogentec (Belgium) attached to a 90 
solid support. The final Fmoc deprotection step was carried out 
using standard conditions. Reversed-phase HPLC analysis (same 
conditions as Fos) revealed that Jun peptide elutes with a 
retention time of 16.6 min. The purification was performed as 
previous described, and the peptide was identified by ESI/MS 95 








Synthesis of the oligonucleotide-peptide hybrids  
The DNA oligos were purchased from Thermo Fisher Scientific. 100 
The conjugation reactions were performed in aqueous buffer 
solution (10 mM Tris·HCl, 100 mM NaCl, pH 7.5) with thiol-
oligo (50 µM) and a threefold excess of the peptide 1 (150 µM). 
The conjugation reaction was monitored by RP-HPLC (Waters 
X-Terra column at a flow rate of 1 mL/min, detection at 220 and 105 
260 nm, gradient 0 to 50 % B over 20 min, A: 5% CH3CN in 
triethylammonium acetate (TEAA) 100 mM, pH 7.0, B: 70% 
CH3CN in TEAA 100 mM, pH 7.0). The oligonucleotide–peptide 
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conjugates were purified by reversed-phase HPLC and were 
identified by MS-MALDI-TOF. C1: tR = 15.9 min, [MH]
+ 
calculated for C359H535N114O178P18S 9880,12, found 9880.66;  
C2: tR = 15.8 min, [MH]
+ calculated for C359H535N114O178P18S 
9880,12, found 9879.60; C3: tR = 15.9 min, [MH]
+ calculated for 5 
C360H535N116O178P18S 9920,13, found 9921.50; C4: tR = 15.4 min, 
[MH]+ calculated for C360H532N125O173P18S 9963,16, found 
9964.57; C2G5T: tR = 15.5 min, [MH]
+ calculated for 
C359H536N111O179P18S 9855,12, found 9854.97; C2C7T: tR = 15.6 
min, [MH]+ calculated for C360H536N113O179P18S 9895,12, found 10 
9896.05. 
Annealing of the conjugates with complementary oligonucleo-
tides  
The oligonucleotide-peptide conjugates were annealed with their 
complementary DNA strands by mixing equimolecular amounts 15 
of each conjugate and its complementary oligonucleotide in 
phosphate buffer 10 mM, NaCl 100 mM, pH 7.5. The solutions 
were heated to 90 ºC for 10 min and then allowed to slowly cool 
to room temperature. 
Binding assays  20 
For gel mobility-shift assays, binding reactions with miniprotein 
Jun were performed over 30 min, at 22 ºC by using ds-
oligonucleotide–peptide conjugates (≈ 50 nM) in a binding 
mixture containing Tris·HCl (18 mM, pH 7.5), KCl (90 mM), 
MgCl2 (1.8 mM), EDTA (1.8 mM), 9 % glycerol, bovine serum 25 
albumin (0.11 mg/mL) and 2.2 % NP-40. Products were resolved 
by using a 15 % nondenaturing polyacrylamide gel and 0.5 
TBE buffer (140 V, 60 min, 22 ºC) and stained with SYBR® Gold 
Nucleic Acid Gel Stain (Molecular Probes) according to the 
standard protocol. 30 
 The titration of Jun was carried out with ≈ 90 pM labelled  
ds-oligonucleotide-peptide conjugate, constructed by annealing 
C2 with a 32P-labelled complementary ss-DNA. The competition 
assays of Fos-Jun complex with conjugate C2ds was carried out 
with ≈ 90 pM 32P-labelled ds-DNA, Jun ≈ 500 nM and Fos ≈ 500 35 
nM with increasing amounts of conjugate C2ds. The experiments 
were carried out in the standard binding buffer at  
22 ºC. The 32P-labelling was carried out using standard kinase 
methods. Products were resolved by PAGE using a 15% 
nondenaturing polyacrylamide gel and 0.5 TBE buffer, and 40 
analysed by autoradiography. 
Fluorescence anisotropy  
Steady-state fluorescence anisotropy measurements were made in 
a Jobin-Yvon Fluoromax-3, (DataMax 2.20), coupled to a 
temperature controller Wavelength Electronics LFI-3751, and 45 
using a standard Hellma semi-micro cuvette (114F-QS, 10 mm 
light path). Titrations were carried out at 22 ºC using the 
following parameters: λex = 495 nm, λem = 518 nm, excitation slit 
width 3.0 nm, emission slit width 12.0 nm, 2 sec integration time, 
each measure was taken in triplicate. Titrations were made by 50 
adding increasing amounts of Jun to a solution containing 50 nM 
labelled ds-oligonucleotide-peptide conjugate, constructed by 
annealing C2 with a fluorescein-labelled complementary ssDNA, 
in 10 mM Tris·HCl, pH 7.5. 
Circular Dichroism  55 
Circular dichroism measurements were made with a Jasco J-715 
coupled to a Neslab RTE-111 termostated water bath, using a 
Hellma 100-QS macro cuvette (2 mm light pass). Measurements 
were made at 22 ºC. Samples contained 10 mM Tris·HCl (pH 
7.5), 100 mM NaCl, 5 µM of C2ds ds-oligonucleotide-peptide 60 
conjugate and 5 µM of Jun. The spectra are the average of 4 
scans and were processed using the “smooth” macro implemented 
in the program Kaleidagraph (v 4.1 by Synergy Software). 
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